VistaGen – On a Mission to Produce Safer & Faster Acting Next-Gen Medicines
Finding Genius Podcast
Richard Jacobs
4.4 • 1K Ratings
🗓️ 4 April 2017
⏱️ 32 minutes
🧾️ Download transcript
Summary
In addition to the AV-101 programs, VistaStem, VistaGen's wholly owned subsidiary, is focused on applying human pluripotent stem cell technology, internally and with collaborators, to discover, rescue, develop and commercialize proprietary new chemical entities (NCEs), including small molecule NCEs with regenerative potential, for CNS and other diseases, and cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells. VistaGen is utilizing its CardioSafe 3D to participate in the FDA's Comprehensive in-vitro Proarrhythmia Assay (CiPA) initiative designed to change the landscape of nonclinical drug development by providing a more complete and accurate assessment of potential drug effects on cardiac risk using stem cell-derived heart cells and in vitro ion channel data.
In this podcast, Dr. Snodgrass discusses VistaStem's stem cell technology applications as well and their CardioSafe 3D™ program.
Make sure to subscribe, review and stay tuned to Future Tech Podcast for more on Future Tech news. Contribute Bitcoin to fuel our interviews and keep us going!
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Welcome to Almost Here, Round the Corner of Future Technology Podcasts with Richard Jacobs. |
| 0:07.0 | Future Technologies always to transform our lives for better or worse are the focus of this podcast. |
| 0:13.0 | Almost here means these technologies are now here and starting to be used. |
| 0:18.0 | We're just around the corner. |
| 0:19.0 | From Bitcoin to artificial intelligence, 3D around the corner, from Bitcoin to artificial intelligence, |
| 0:22.0 | 3D printing, blockchain, virtual reality, and more. |
| 0:26.1 | Hello, this is Richard Jacobs with Future Tech Podcast. |
| 0:29.5 | My guest today is Dr. Ralph Snodgrass, founder and president of Vistigen Therapeutics. |
| 0:35.9 | Dr. Snigras, how you doing? |
| 0:39.3 | Doing very well, Richard. Thanks very much. |
| 0:40.3 | I appreciate talking to you today. |
| 0:42.3 | Yeah. |
| 0:43.3 | So if you would let listeners know what are the main project |
| 0:48.3 | or projects at Vistigen, what are you guys working on? |
| 0:51.3 | Sure. |
| 0:52.3 | Well, Vistigen is a NASDAQ-LESTED BIO-Farmaceutical company that's developing small molecule |
| 1:01.5 | drugs for major CNS conditions. |
| 1:05.6 | We're in phase two clinical studies for a lead drug candidate in major depression and has also applications |
| 1:14.4 | in other CNS indications such as neuropathic pain, epilepsy, and neurodegenerative diseases |
| 1:23.8 | like Parkinson's and Huntington's disease. |
| 1:29.0 | I think what I want to talk to you about today is about some of our stem cell technologies. |
| 1:36.5 | Vista stem is a wholly owned subsidiary of Vistigen. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Richard Jacobs, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Richard Jacobs and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.